NEPHROCARE HEALTH SERV L
NEPHROPLUS · General/Diversified · NSE
₹671
Current Market Price
Fair Value (DCF)
₹283
Discount to FV
-57.9%
Updated just now
YieldIQ Score
40/100
Piotroski F-Score
7/9
Economic Moat
Moderate
Confidence
50%
ROE
6.9%
Debt/Equity
0.07
WACC
11.1%
Market Cap
₹6,733 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
20.8%
Return on capital employed
EV / EBITDA
24.9×
Enterprise multiple
Debt / EBITDA
0.4×
Leverage vs earnings
Interest Coverage
5.6×
EBIT covers interest
Current Ratio
1.92×
Short-term liquidity
Asset Turnover
1.00×
Revenue per ₹ of assets
Revenue CAGR (3Y)
34.1%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹671.05
Bear case
Discount -289.6%
Base case
Discount -137.5%
Bull case
Discount -91.0%
Ratio Trends
NEPHROPLUS · last 5 annual periods
ROE
6.9%
ROCE
20.8%
Operating Margin
—
Debt / Equity
0.07×
PE
—
EV / EBITDA
—
Historical Financials
NEPHROPLUS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 yfinance | 2024 yfinance | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹474 Cr | ₹415 Cr | ₹540 Cr | ₹756 Cr | ₹999 Cr | +20.5% |
| EBITDA | ₹122 Cr | ₹52.9 Cr | ₹107 Cr | ₹181 Cr | ₹248 Cr | +19.5% |
| EBIT | ₹79.0 Cr | ₹6.0 Cr | ₹52.2 Cr | ₹106 Cr | — | +7.7% |
| PAT | ₹14.2 Cr | ₹-11.8 Cr | ₹35.1 Cr | ₹67.1 Cr | ₹76.8 Cr | +52.4% |
| EPS (diluted) | — | ₹-1.17 | ₹3.50 | ₹6.69 | — | — |
| CFO | ₹38.1 Cr | ₹11.3 Cr | ₹72.3 Cr | ₹135 Cr | ₹233 Cr | +57.2% |
| CapEx | ₹-61.3 Cr | ₹-73.7 Cr | ₹-80.0 Cr | ₹-101 Cr | ₹-119 Cr | — |
| FCF | ₹-23.2 Cr | ₹-62.5 Cr | ₹-7.7 Cr | ₹34.5 Cr | ₹113 Cr | — |
| Total Assets | ₹1194 Cr | ₹666 Cr | ₹806 Cr | ₹996 Cr | ₹1471 Cr | +5.4% |
| Total Debt | ₹261 Cr | ₹214 Cr | ₹268 Cr | ₹258 Cr | ₹79.7 Cr | -25.7% |
| Shareholders' Equity | ₹717 Cr | ₹389 Cr | ₹414 Cr | ₹584 Cr | ₹1116 Cr | +11.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
NEPHROPLUS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 YATHARTH YATHARTH | — | — | Pending | 8.0% | — |
JLHL JLHL | — | — | Pending | 12.6% | — |
 HCG HCG | — | — | Pending | 1.0% | 569.9× |
JSLL JSLL | — | — | Pending | 33.2% | — |
PARKHOSPS PARKHOSPS | — | — | Pending | 19.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for NEPHROPLUS in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. NEPHROCARE HEALTH SERV L (NEPHROPLUS.NS) trades at 671.05 vs a model fair value of 282.52, a gap of -57.9%. Piotroski F-score: 7/9. Moat ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of NEPHROPLUS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for NEPHROPLUS →
Compare
Head-to-head with peers
Compare NEPHROPLUS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse NEPHROPLUSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.